50419-393 : Vitrakvi 20 mg/ml Oropharyngeal Solution, Concentrate


NDC: 50419-393
Labeler: Bayer Healthcare Pharmaceuticals Inc.
Product Type: Human Prescription Drug
Drug Name:  Vitrakvi
Dosage Form: Oropharyngeal Solution, Concentrate
Application #: NDA211710
Rev. Date: 


NDC Package Codes:

  • 50419-393-03: 2 BOTTLE IN 1 CARTON (50419‑393‑03) / 50 ML IN 1 BOTTLE (50419‑393‑02)

Active Ingredients:

  • Larotrectinib

Dosage Strength:

  • 20 mg/mL

Pharmaceutical Classes:

  • Kinase Inhibitor [EPC]
  • Tropomyosin Receptor Kinases Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 50419-390 Vitrakvi 25 mg Oral Capsule by Bayer Healthcare Pharmaceuticals Inc.
  • 50419-391 Vitrakvi 100 mg Oral Capsule by Bayer Healthcare Pharmaceuticals Inc.
  • 50419-392 Vitrakvi 20 mg/ml Oropharyngeal Solution, Concentrate by Bayer Healthcare Pharmaceuticals Inc.
  • 71777-390 Vitrakvi 25 mg Oral Capsule by Loxo Oncology, Inc.
  • 71777-391 Vitrakvi 100 mg Oral Capsule by Loxo Oncology, Inc.
  • 71777-392 Vitrakvi 20 mg/ml Oral Solution by Loxo Oncology, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 50419-393 QR Code

< Prev: 50419-392Next: 50419-395 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.